Reported 1 day ago
Jim Cramer criticized the market's harsh response to Amgen’s stock following the announcement of new data on its drug MariTide. He pointed out that unlike similar treatments requiring weekly injections, MariTide only needs to be administered monthly, which he prefers. Despite some positive findings from recent trials, Cramer believes the stock's decline was unwarranted.
Source: YAHOO